Press Releases

Year

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

TCER ® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity in vivo and reduced T cell engager-associated toxicities as part of overall favorable in vitro

Sep 10, 2022

PDF Version

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

IMA203CD8 is a 2 nd -generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8 showed enhanced potency and prolonged anti-tumor activity mediated by activated TCR-engineered CD4 T

Aug 23, 2022

PDF Version

Immatics Announces Second Quarter 2022 Financial Results and Business Update

ACTengine ® TCR-T cell therapy targeting PRAME is enrolling patients in all three P hase 1b cohorts : IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A) , IMA203/ nivolumab checkpoint inhibitor combination (Cohort B) and IMA203CD8 2 nd gen eration monotherapy (Cohort C)

Aug 09, 2022

PDF Version

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

Tuebingen, Germany ; Houston, Texas; and Cambridge, Mass., June 7, 2022 – Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc.

Jun 07, 2022

PDF Version

Immatics Announces First Quarter 2022 Financial Results and Business Update

ACTengine® IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with 2 nd -generation IMA203CD8 granted Phase 1 clinical trial initiated with the first T cell engaging

Jun 02, 2022

PDF Version

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo ® with Bristol Myers Squibb’s technologies and oncology drug development expertise Immatics to receive upfront payment of $ 60 million and

Jun 02, 2022

PDF Version

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab 1 , a PD-1 immune checkpoint inhibitor, in patients with multiple solid tumors Initiation of the combination treatment follows

May 18, 2022

PDF Version

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors TCER® IMA401 targets MAGEA4/8 and will be developed in

May 10, 2022

PDF Version

Immatics Announces Full Year 2021 Financial Results and Corporate Update

IMA203 TCR-T candidate targeting PRAME demonstrated a 50 % objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation M ultiple IMA203 Ph ase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level , checkpoint

Mar 23, 2022

PDF Version

Press Releases

Press Contact

Press Releases